Complications of intravitreal injections

Current Opinion in Ophthalmology

Volumn 21, Issue 3, 2010, Pages 178-183

  Sampat, Kapil M ^a   Garg, Sunir J ^b  

^a PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cataract; Complications; Endophthalmitis; Intravitreal injection

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BEVACIZUMAB; CASPOFUNGIN; CEFTAZIDIME; FOLINIC ACID; FOSCARNET; GANCICLOVIR; GENTAMICIN; METHOTREXATE; NATAMYCIN; NYSTATIN; PEGAPTANIB; RANIBIZUMAB; SILICONE OIL; TRIAMCINOLONE; TRIAZOLE DERIVATIVE; VANCOMYCIN; VASCULOTROPIN INHIBITOR; VERTEPORFIN; VORICONAZOLE;

ADD ON THERAPY; BLOOD BRAIN BARRIER; CATARACT; CATARACTOGENESIS; CHORIORETINOPATHY; CLINICAL PRACTICE; CLINICAL TRIAL; COLOR VISION; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOPHTHALMITIS; EYE INFLAMMATION; FUNGAL ENDOPHTHALMITIS; GLAUCOMA; GRAM NEGATIVE AEROBIC RODS AND COCCI; GRAM POSITIVE BACTERIUM; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; INFECTION RISK; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; KERATOPATHY; LIVER FUNCTION; LOW DRUG DOSE; LYMPHOMA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETINA DETACHMENT; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULOPATHY; RETINA TEAR; RETINITIS; REVIEW; SAFETY; SIDE EFFECT; UVEITIS; VISUAL DISORDER; VISUAL HALLUCINATION; VITREORETINOPATHY; VITREOUS BODY DETACHMENT;

CATARACT; ENDOPHTHALMITIS; EYE DISEASES; HUMANS; INJECTIONS; VITREOUS BODY;

EID: 77951295054     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e328338679a     Document Type: Review

References (95)

1. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina 2009; 29:875-912.
2. Mavrikakis E, Lam WC. Current trends of intravitreal steroid use in retinal diseases. Can J Ophthalmol 2009; 44:147-153.
3. Kramar M, Vu L, Whitson JT, He YG. The effect of intravitreal triamcinolone on intraocular pressure. Curr Med Res Opin 2007; 23:1253-1258.
4. Konstantopoulos A, Williams CP, Newson RS, Luff AJ. Ocular morbidity associated with intravitreal triamcinolone acetonide. Eye 2007; 21:317-320.
5. Kok H, Lau C, Maycock N, et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005; 112:1916-1916.e7.
6. Khairallah M, Zeghidi H, Ladjimi A, Yahia SB, et al. Primary intravitreal triamcinolone acetonide for diabetic massive macular hard exudates. Retina 2005; 25:835-839.
7. Karacorlu M, Ozdemir H, Karacorlu S. Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema. Acta Ophthalmol Scand 2003; 81:648-652.
8. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003; 34:386-390.
9. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005; 140:695-702.
10. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 2001; 29:2-6.
11. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol 1999; 27:431-432.
12. Gillies MC, Simpson JM, Bilson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004; 122:336-340.
13. Jonas JB, Spandau UH, Harder B, et al. Intereye difference in exudative agerelated macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2005; 139:1073-1079.
14. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003; 87:24-27. (Pubitemid 36071773)
15. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109:920-927.
16. A randomized trial comparing intravitreal triamcinolone acetonide and focal/ grid photocoagulation for diabetic macular edema. Ophthalmology, 2008. 115: p. 1447-1449, 1449 e1-10
17. Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127:1115-1128.
18. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127:1101-1114.
19. Lo WR, Rowlette LL, Caballero M, et al. Tissue differential microarray analysis of dexamethasone induction reveals potential mechanisms of steroid glaucoma. Invest Ophthalmol Vis Sci 2003; 44:473-485.
20. Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 2005; 40:63-68.
21. Avci R, Kaderli B, Akalp FD. Intravitreal triamcinolone injection for chronic diffuse diabetic macular oedema. Clin Experiment Ophthalmol 2006; 34:27-32. (Pubitemid 43379367)
22. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004; 138:740-743.
23. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112:593-598. (Pubitemid 41108858)
24. Krepler K, Ergun E, Sacu S, et al. Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study. Acta Ophthalmol Scand 2005; 83:600-604. (Pubitemid 41488636)
25. Androudi S, Letko E, Meniconi M, et al. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm 2005; 13:205-212.
26. Cekic O, Chang S, Tseng JJ, et al. Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 2005; 139:993-998.
27. Jonas JB, Degenring R, Vossmerbauemer U, Kamppeter B. Frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide. Eur J Ophthalmol 2005; 15:462-464. (Pubitemid 41152966)
28. Islam MS, Vernon SA, Negi A. Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years. Eye 2007; 21:321-323.
29. Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol 2006; 141:629-637.
30. Gillies MC, Kuzniarz M, Craig J, et al. Intravitreal triamcinolone- induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005; 112:139-143.
31. Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127:245-251.
32. Bucher RS, Hall E, Reed DM, et al. Effect of intravitreal triamcinolone acetonide on susceptibility to experimental bacterial endophthalmitis and subsequent response to treatment. Arch Ophthalmol 2005; 123:649-653.
33. Jonas JB, Kreissig I, Degenring RF. Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol 2003; 121:1663-1664. (Pubitemid 37392386)
34. Westfall AC, Osborn A, Kuhl D, et al. Acute endophthalmitis incidence: intravitreal triamcinolone. Arch Ophthalmol 2005; 123:1075-1077.
35. Moshfeghi DM, Kaiser PK, Bakri SJ, et al. Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging 2005; 36:24-29.
36. Nelson ML, Tennant MT, Sivalingam A, et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003; 23:686-691.
37. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003; 136:791-796.
38. Jager RD, Aiello LP, Patel SC, CunninghamET. Risks of intravitreous injection: a comprehensive review. Retina 2004; 24:676-698.
39. Roth DB,Chieh J,SpirnMJ, et al.Noninfectious endophthalmitis associatedwith intravitreal triamcinolone injection. Arch Ophthalmol 2003; 121:1279-1282.
40. Wang LC, Yang CM. Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide. Ocul Immunol Inflamm 2005; 13:295-300.
41. Jonisch J, Lai JC, Deramo VA, et al. Increased incidence of sterile endophthalmitis following intravitreal preserved triamcinolone acetonide. Br J Ophthalmol 2008; 92:1051-1054.
42. Sharma MC, Lai WW, Shapiro MJ. Pseudohypopyon following intravitreal triamcinolone acetonide injection. Cornea 2004; 23:398-399.
43. Moshfeghi AA, Scott IU, Flynn HW, Puliafito CA. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 2004; 138:489-492.
44. Lam A, Garg SJ, Spirn M, Fineman M, Sivalingam A. Sterile endophthalmitis following intravitreal injection of preservative-free triamcinolone acetonide. Retinal Cases and Brief Reports 2008; 2:228-230.
45. Yu SY, Damico M, Viola F, et al. Retinal toxicity of intravitreal triamcinolone acetonide: a morphological study. Retina 2006; 26:531-536.
46. Lang Y, Zemel E, Miller B, Perlman I. Retinal toxicity of intravitreal kenalog in albino rabbits. Retina 2007; 27:778-788. (Pubitemid 47051776)
47. Albini TA, Abd-El-Barr MM, Carvounis PE, et al. Long-term retinal toxicity of intravitreal commercially available preserved triamcinolone acetonide (Kenalog) in rabbit eyes. Invest Ophthalmol Vis Sci 2007; 48:390-395.
48. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980; 90:810-816.
49. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-1444.
50. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of theANCHORstudy.Ophthalmology 2009; 116:57-65.e5.
51. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006; 355:1419-1431.
52. Singerman LJ,Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008; 92:1606-1611.
53. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246:81-87.
54. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008; 28:1395-1399.
55. Mason JO 3rd, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008; 28:564-567.
56. Diago T, McCannel CA, Bakri SJ, et al. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 2009; 29:601-605.
57. Antoszyk AN, Tuomi L, Chung CY, Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008; 145:862-874.
58. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, shamcontrolled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145:239-248.
59. Brown GC, Eagle RC, Shakin EP, et al. Retinal toxicity of intravitreal gentamicin. Arch Ophthalmol 1990; 108:1740-1744.
60. Campochiaro PA, Lim JI. Aminoglycoside toxicity in the treatment of endophthalmitis. The Aminoglycoside Toxicity Study Group. Arch Ophthalmol 1994; 112:48-53.
61. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol 1995; 113: 1479-1496.
62. Hegazy HM, Kivilcim M, Peyman GA, et al. Evaluation of toxicity of intravitreal ceftazidime, vancomycin, and ganciclovir in a silicone oil-filled eye. Retina 1999; 19:553-557.
63. Heinemann MH. Characteristics of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Am J Med 1992; 92 (2A):12S-16S.
64. Holland GN, Shuler JD. Progression rates of cytomegalovirus retinopathy in ganciclovir-treated and untreated patients. Arch Ophthalmol 1992; 110:1435-1442.
65. Cantrill HL,Henry K,Melroe NH, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results. Ophthalmology 1989; 96:367-374.
66. Arevalo JF, Garcia RA, Mendoza AJ. High-dose (5000-microg) intravitreal ganciclovir combined with highly active antiretroviral therapy for cytomegalovirus retinitis in HIV-infected patients in Venezuela. Eur J Ophthalmol 2005; 15:610-618.
67. Young S, Morlet N, Besen G, et al. High-dose (2000-microgram) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis. Ophthalmology 1998; 105:1404-1410.
68. Cochereau-Massin I, Lehoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1991; 98:1348-1353; discussion 1353-1355.
69. Heinemann MH. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol 1989; 107:1767-1772.
70. Scott IU, Luu KM, Davis JL. Intravitreal antivirals in the management of patients with acquired immunodeficiency syndrome with progressive outer retinal necrosis. Arch Ophthalmol 2002; 120:1219-1222.
71. Ussery FM 3rd, Gibson SR, Conklin RH, et al. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology 1988; 95:640-648.
72. Baudouin C, Chassain C, Caujolle C, Gastaud P. Treatment of cytomegalovirus retinitis in AIDS patients using intravitreal injections of highly concentrated ganciclovir. Ophthalmologica 1996; 210:329-335.
73. Hodge WG, Lalonde RG, Sampalis J, Deschenes J. Once-weekly intraocular injections of ganciclovir for maintenance therapy of cytomegalovirus retinitis: clinical and ocular outcome. J Infect Dis 1996; 174:393-396.
74. Kernt M, Neubauer AS, De Kaspar HM, Kampik A. Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis. Retina 2009; 29:362-370.
75. Gao H, Pennesi ME, Shah K, et al. Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch Ophthalmol 2004; 122:1687-1692.
76. Hariprasad SM, Mieler WF, Lin TK, et al. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol 2008; 92:871-878.
77. Shen YC, Wang MY, Wang CY, et al. Clearance of intravitreal voriconazole. Invest Ophthalmol Vis Sci 2007; 48:2238-2241.
78. Zarkovic A, Guest S. Scedosporium apiospermum traumatic endophthalmitis successfully treated with voriconazole. Int Ophthalmol 2007; 27:391-394.
79. Hardwig PW, Pulido JS, Erie JC, et al. Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol 2006; 142:883-885.
80. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002; 109:1709-1716.
81. Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol 2008; 92:383-388.
82. Hardwig PW, Pulido JS, Bakri SJ. The safety of intraocular methotrexate in silicone-filled eyes. Retina 2008; 28:1082-1086.
83. Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology 1991; 98:1769-1775.
84. Shah, C., et al. Postintravitreal anti-VEGF injection endophthalmitis: risk factors of an outbreak and outcomes of an intervention, in Retina Congress. October 2 2009: New York, New York.
85. Isenberg SJ, Apt L, Yoshimori R, Khwarg S. Chemical preparation of the eye in ophthalmic surgery. IV. Comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol 1985; 103:1340-1342.
86. Grimes SR, Mein CE, Trevino S. Preoperative antibiotic and povidone-iodine preparation of the eye. Ann Ophthalmol 1991; 23:263-266.
87. Ta CN, Egbert PR, Singh K, et al. Prospective randomized comparison of 3-day versus 1-h preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology 2002; 109:2036-2040; discussion 2040-2041.
88. Wheatly H. Inferior intravitreal injection site associated with higher incidence of post-injection endophthalmitis. In: Retina Congress. October 3 2009. New York, New York.
89. Bhavsar AR, Googe JM, Stockdale CR, et al. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Diabetic Retinopathy Clinical Research Network. Arch Ophthalmol 2009; 127:1581-1583.
90. Scott IU, Flynn HW Jr. Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007; 27:10-12.
91. Ta CN. Minimizing the risk of endophthalmitis following intravitreous injections. Retina 2004; 24:699-705.
92. Garg SJ, Recchia FM. Re: evolving guidelines for intravitreous injections. Retina 2005; 25:949-950; author reply 950.
93. Bakri SJ, Ekdawi NS. Intravitreal silicone oil droplets after intravitreal drug injections. Retina 2008; 28:996-1001.
94. Freund KB, Laud K, Eandi CM, Spaide RF. Silicone oil droplets following intravitreal injection. Retina 2006; 26:701-703.
95. Scott IU, Oden NL, VanVeldhuisen PC, et al. SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs. luer cone syringe design. Am J Ophthalmol 2009; 148:725-732.e7.